Aktis Oncology (AKTS) Earnings Analysis
Aktis Oncology (AKTS) next reports earnings on 2026-08-10, consensus EPS -0.44 USD. Last quarter (2026-05-11) it missed with EPS -0.38 USD vs -0.31 USD est (-22.6%). It has beaten estimates in 1/2 recent quarters (50%). Trailing P/E -40.67.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does AKTS next report earnings?
| Next earnings date | 2026-08-10 |
|---|---|
| Consensus EPS estimate | -0.44 USD |
| Revenue estimate | 0.00B |
AKTS earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-05-11 | -0.38 USD | -0.31 USD | -22.6% | Miss |
| 2026-03-30 | -18.19 USD | -21.59333 USD | +15.8% | Beat |
Beat rate: 1/2 (50%) over reported quarters with consensus data.
AKTS valuation and analyst view
| Trailing P/E | -40.67 |
|---|---|
| Trailing EPS | -0.60538 USD |
| Price / book | 2.71 |
| Dividend yield | 0.00% |
| Market cap | 1.31B |
| Analyst consensus | Buy (5 buy / 3 hold / 0 sell) |
| Avg price target | 37.5 USD |
Related research pages
Frequently asked questions
When is Aktis Oncology (AKTS)'s next earnings date?
Aktis Oncology is next scheduled to report on 2026-08-10, with a consensus EPS estimate of -0.44 USD and revenue estimate of 0.00B.
Did AKTS beat earnings last quarter?
In its 2026-05-11 report, AKTS posted EPS of -0.38 USD versus a -0.31 USD estimate — a miss of 22.6%.
What is AKTS's earnings track record?
Over the last 2 reported quarters with consensus data, AKTS beat estimates 1 times (50%).
What is AKTS's current P/E ratio and EPS?
AKTS trades at a trailing P/E of -40.67 on trailing EPS of -0.6053802735364353 USD.
What do analysts rate AKTS?
Analyst consensus is "Buy" across 8 ratings (0 strong buy, 5 buy, 3 hold, 0 sell, 0 strong sell). Average 12-month price target: 37.5 USD.